The starting price implies a revaluation of more than 500% compared to the value of the company in 2003, when Najeti, a French risk capital company, bought 35% of Oryzon. <\/p>\n
This operation is included in Oryzon’s strategic growth plan, which comprises several measures to rapidly increase the growth potential of Oryzon and boost its future launch into the market. <\/p>\n
Part of the resources acquired will be devoted to funding a new R+D laboratory at the Parc Cientific de Barcelona<\/i> (PCB, Barcelona Science Park), in a new building that is scheduled for completion mid 2007. This new lab will allow the company to double the size of its present facilities. <\/p>\n
In addition, Oryzon aims to speed up its internal and co-development R+D programmes, which include its programme devoted to the early detection of Alzheimer’s disease. The director of Oryzon has said, “The agreement involves a valuation that gives a fair reflection of the added value of our company and its potential for growth. The addition of an industrial partner is included in Oryzon’s strategic collaboration programme with the Spanish pharmaceutical industry, defined in the ONCNOSIS consortium. The presence of the Grupo FERRER<\/i> as a minority shareholder reflects confidence in the potential of the biotech sector for the pharmaceutical industry. Furthermore, it reflects our wish to strengthen relations with FERRER but without losing our independence and maintaining our intention to collaborate with other national and international companies in the pharmaceutical sector”. <\/p>\n","protected":false},"excerpt":{"rendered":"